(2E)-N-(2,3-二氢-1,4-苯并二噁英-6-基)-3-[4-(1,1-二甲基乙基)苯基]-2-丙酰胺

生物活性靶点体外研究体内研究 (2E)-N-(2,3-二氢-1,4-苯并二噁英-6-基)-3-[4-(1,1-二甲基乙基)苯基]-2-丙酰胺试剂级价格

CAS号:545395-94-6
英文名:AMG 9810
中文名:(2E)-N-(2,3-二氢-1,4-苯并二噁英-6-基)-3-[4-(1,1-二甲基乙基)苯基]-2-丙酰胺
CBNumber:CB0306302
分子式:C21H23NO3
分子量:337.41
MOL File:545395-94-6.mol

(2E)-N-(2,3-二氢-1,4-苯并二噁英-6-基)-3-[4-(1,1-二甲基乙基)苯基]-2-丙酰胺化学性质

沸点 :512.5±50.0 °C(Predicted)
密度 :1.175±0.06 g/cm3(Predicted)
储存条件 :2-8°C
溶解度 :DMSO: >5mg/mL
酸度系数(pKa) :12.22±0.20(Predicted)
形态 :powder
颜色 :white to beige

安全信息

危险品标志 :Xn
危险类别码 :22
WGK Germany :3

(2E)-N-(2,3-二氢-1,4-苯并二噁英-6-基)-3-[4-(1,1-二甲基乙基)苯基]-2-丙酰胺性质、用途与生产工艺

生物活性 AMG-9810 是一种有效的、竞争性和选择性的 vanilloid receptor 1 (TRPV1) 的拮抗剂，可抑制辣椒素capsaicin的活化，对人TRPV1和大鼠TRPV1的IC50值分别为24.5 nM和85.6 nM。AMG-9810 可阻止所有已知模式的TRPV1激活，包括protons-，heat-和endogenous ligands，例如anandamide，N-arachidonyl dopamine和oleoyldopamine。AMG-9810 可显著降低 TLR2 和 TLR4 的mRNA表达。AMG-9810 还可通过 EGFR/Akt/mTOR 信号通路来促进小鼠皮肤肿瘤发生的缓解。
靶点
Target Value
TLR2
()
TLR4
()
hTRPV1
(Cell-free assay) 24.5 nM
rTRPV1
(Cell-free assay) 85.6 nM
体外研究

AMG9810 is a competitive antagonist of capsaicin activation (IC ₅₀ value for human TRPV1, 24.5±15.7 nM; rat TRPV1, 85.6±39.4 nM) and blocks all known modes of TRPV1 activation, including protons (IC ₅₀ value for rat TRPV1, 294±192 nM; human TRPV1, 92.7±72.8 nM), heat (IC ₅₀ value for rat TRPV1, 21±17 nM; human TRPV1, 15.8±10.8 nM), and endogenous ligands, such as anandamide, N-arachidonyl dopamine, and oleoyldopamine. AMG9810 blocks capsaicin-evoked depolarization and calcitonin gene-related peptide release in cultures of rat dorsal root ganglion primary neurons. AMG9810 inhibits capsaicin-, proton-, heat-, and endogenous ligand-induced uptake of ⁴⁵ Ca ²⁺ into TRPV1-expressing cells.
体内研究

AMG9810 is effective at preventing capsaicin-induced eye wiping in a dose-dependent manner, and it reverses thermal and mechanical hyperalgesia in a model of inflammatory pain induced by intraplantar injection of complete Freund's adjuvant. At effective doses, AMG9810 does not show any significant effects on motor function. AMG9810 is the first cinnamide TRPV1 antagonist reported to block capsaicin-induced eye wiping behavior and reverse hyperalgesia in an animal model of inflammatory pain. AMG9810, promotes mouse skin tumor development. The topical application of AMG9810 results in a significant increase in the expression level of the epidermal growth factor receptor (EGFR) and its downstream Akt/mammalian target of rapamycin (mTOR)-signaling pathway.